inspiremd.com - יחס שווי חברה להכנסות NSPR

InspireMD, Inc. (NSPR) develops advanced CGuard cardiovascular systems, investing in minimally invasive brain protection. The EV/Sales shift demonstrates market value dynamics, where 1618.37 characterizes this valuation metric. Production in Germany and Israel is based on the unique MicroNet technology. The company is currently actively commercializing its stent line, offering surgeons more effective stroke prevention methods.
NSPR (InspireMD Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Investors utilize this ratio to stress-test asset value by assessing market capitalization and net debt relative to sales volume. As InspireMD, Inc. (NSPR) scales the production of cardiovascular stents and reduces unit costs, the enterprise value-to-revenue ratio helps determine how effectively operating leverage justifies the current equity premium.